Charles Schwab Investment Management Inc. Acquires 1,092 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE)

Charles Schwab Investment Management Inc. lifted its holdings in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) by 0.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 149,206 shares of the company’s stock after acquiring an additional 1,092 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Pulse Biosciences were worth $2,598,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of PLSE. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Pulse Biosciences during the 3rd quarter valued at about $588,000. State Street Corp lifted its position in Pulse Biosciences by 17.8% during the third quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after purchasing an additional 69,696 shares during the period. Barclays PLC lifted its position in Pulse Biosciences by 361.4% during the third quarter. Barclays PLC now owns 30,306 shares of the company’s stock valued at $530,000 after purchasing an additional 23,738 shares during the period. Geode Capital Management LLC boosted its holdings in Pulse Biosciences by 7.8% in the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after purchasing an additional 33,200 shares during the last quarter. Finally, Franklin Resources Inc. bought a new stake in Pulse Biosciences in the 3rd quarter worth approximately $378,000. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Price Performance

PLSE stock opened at $15.66 on Friday. The business’s 50-day moving average is $18.83 and its two-hundred day moving average is $18.17. Pulse Biosciences, Inc. has a fifty-two week low of $6.60 and a fifty-two week high of $25.00.

Analyst Ratings Changes

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a report on Thursday, January 2nd.

Pulse Biosciences Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.